Soros Fund Management’s Ionis Pharmaceuticals IONS Stock Holding History

Soros Fund Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10,700	Closed	-$544K	–	251
2017 Q2	$544K	Buy	+10,700	New	+$498K	0.01%	128
2017 Q1	–	Sell	-4,300	Closed	-$206K	–	302
2016 Q4	$206K	Buy	+4,300	New	+$170K	﹤0.01%	199
2016 Q1	–	Sell	-12,000	Closed	-$743K	–	268
2015 Q4	$743K	Buy	+12,000	New	+$648K	0.01%	169
2014 Q2	–	Sell	-5,539	Closed	-$239K	–	404
2014 Q1	$239K	Buy	+5,539	New	+$268K	﹤0.01%	300

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Soros Fund Management's IONS Position: Q3 2017 in Review

Soros Fund Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2017, closing a stake of 10,700 shares — an estimated $544K sold.

Soros Fund Management first reported a position in IONS in Q1 2014 and held it in 4 quarters. The position peaked at $743K in Q4 2015. 301 funds tracked by Wall St. Rank hold IONS as of Q3 2017.

Soros Fund Management reported no remaining Ionis Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Soros Fund Management sold 10,700 Ionis Pharmaceuticals shares in Q3 2017, an estimated $544K.
Soros Fund Management first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 4 quarters.
Soros Fund Management's Ionis Pharmaceuticals position peaked at $743K in Q4 2015.
301 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2017.

Based on Soros Fund Management's 13F filing for Q3 2017, filed 14 Nov 2017.